Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Gilde Healthcare Partners. (3/31/20). "Press Release: Gilde Healthcare Raises €416 million ($450 million) Venture and Growth Capital Fund". Utrecht & Cambridge, MA.

Organisations Organisation Gilde Healthcare Partners B.V.
  Group Gilde Investment (Group)
  Organisation 2 Koninklijke Philips Electronics N.V. (NYSE: PHG, AEX: PHI)
  Today Koninklijke Philips N.V. (NYSE: PHG, AEX: PHI)
  Group Philips (Group)
Products Product Gilde Healthcare V fund (GHC V)
  Product 2 healthcare
Index term Index term Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments
     


Gilde Healthcare today announces the first and final close of Gilde Healthcare V, a €416 million ($450 million) venture and growth capital fund. The new fund, which was oversubscribed, targets growth opportunities in a broad range of healthcare sectors including digital health, medtech and therapeutics both in Europe and North America. The fund will have a special attention for private healthcare companies enabling improved care at affordable cost.

Gilde Healthcare V was raised in a single close and is backed by a balanced mix of international investors including banks, pension funds, fund-of-funds, sovereign funds, endowments, family offices, entrepreneurs and Gilde partners. Disclosed investors include longstanding corporate partner Royal Philips and Rabo Corporate Investments from The Netherlands, HANIEL and KfW Capital from Germany, BNP Paribas Fortis Private Equity and Belgian Growth Fund from Belgium, Danish Growth Fund from Denmark and the European Investment Fund (EIF) from Luxembourg.

Pieter van der Meer, Managing Partner of Gilde Healthcare, said: "The healthcare landscape in Europe and the US is changing rapidly, driven by the need for more patient centric care and more focus on value based care. With our new fund we will continue our strategy to invest in venture and growth stage companies developing novel solutions that enable better healthcare outcomes at reduced costs. An example is remote monitoring and home care of patients which is now more relevant than ever in the fight against COVID-19."

Recent Gilde Healthcare exits include the sale of infectious disease (including COVID-19) diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath Therapeutics (treatment of lung transplant rejection) to Zambon Pharma and the NASDAQ listing of Axonics, focused on the treatment of overactive bladder. Gilde Healthcare also has a strong track record with healthcare unicorns such as Ablynx, Ascendis Pharma and uniQure.

Gilde Healthcare's team is a mix of investment managers, sector experts and serial entrepreneurs. The trans-Atlantic team provides hands-on support to its companies on their international growth paths. The Gilde Healthcare V fund will typically make equity investments in a single portfolio company of between €10-40 million.


About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare's venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare's private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.


For more information, visit the company's website at www.gildehealthcare.com.

Media Contact

Gilde Healthcare
Pieter van der Meer
Managing Partner
+31 (0)30 219 2565

CFF Communications
Suzanne Bakker
+31 (0)6 1136 8659
suzanne.bakker@cffcommunications.nl
Eline Weltevreede
+31 (0)6 1136 8648
eline.weltevreede@cffcommunications.nl

   
Record changed: 2020-04-01

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Gilde Investment (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px




» top